Amgen Inc. $AMGN Stake Lowered by IFG Advisory LLC

IFG Advisory LLC reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 58.2% during the 3rd quarter, HoldingsChannel reports. The fund owned 3,780 shares of the medical research company’s stock after selling 5,273 shares during the period. IFG Advisory LLC’s holdings in Amgen were worth $1,593,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Quest 10 Wealth Builders Inc. grew its stake in Amgen by 220.0% in the third quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 55 shares in the last quarter. Wellington Altus USA Inc. increased its position in Amgen by 72.3% in the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock worth $28,000 after purchasing an additional 34 shares during the last quarter. Nvwm LLC increased its position in Amgen by 412.5% in the 3rd quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock worth $35,000 after purchasing an additional 66 shares during the last quarter. PFS Partners LLC raised its stake in shares of Amgen by 95.5% during the 3rd quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock worth $36,000 after purchasing an additional 42 shares in the last quarter. Finally, TOWER TRUST & INVESTMENT Co purchased a new stake in shares of Amgen during the 3rd quarter worth about $38,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Trading Down 0.7%

Amgen stock opened at $462.32 on Tuesday. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.20. The company has a market capitalization of $250.07 billion, a price-to-earnings ratio of 26.82, a PEG ratio of 3.25 and a beta of 0.43. Amgen Inc. has a one year low of $312.39 and a one year high of $483.99. The company’s fifty day moving average price is $425.81 and its two-hundred day moving average price is $381.77.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, beating the consensus estimate of $5.79 by $0.66. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The company had revenue of $10.37 billion for the quarter, compared to analyst estimates of $10.07 billion. During the same period last year, the company earned $5.64 earnings per share. The business’s revenue was up 8.5% compared to the same quarter last year. On average, analysts forecast that Amgen Inc. will post 23.37 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be issued a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. Amgen’s dividend payout ratio is currently 58.47%.

Analyst Ratings Changes

Several brokerages have recently issued reports on AMGN. Leerink Partners lifted their price target on Amgen from $395.00 to $464.00 and gave the company a “market perform” rating in a report on Thursday, November 5th. Jefferies Financial Group restated a “hold” rating and issued a $410.00 price objective on shares of Amgen in a report on Wednesday, September 23rd. The Goldman Sachs Group increased their price objective on Amgen from $481.00 to $536.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. Truist Financial raised their price objective on shares of Amgen from $380.00 to $398.00 and gave the company a “hold” rating in a research report on Wednesday, November 4th. Finally, Bank of America lifted their target price on shares of Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, eighteen have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $425.69.

Check Out Our Latest Stock Analysis on Amgen

Amgen Profile

(Free Report)

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

Recommended Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.